Esophageal Stents Market By Product Type (Fully Covered Stents, Partially Covered Stents, Uncovered Stents); By Material (Metal, Plastic); By Application (Malignant Esophageal Strictures, Benign Esophageal Strictures, Esophageal Fistulas & Leaks, Others); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Esophageal Stents Market  – Market Size, Clinical Use, Technology, Regional Opportunity and Competitive Landscape, 2026–2032 - (Updated On: 31-Aug-2026)

What Is the Esophageal Stents Market Size and How Is Its Clinical Device Landscape Evolving?

The Global Esophageal Stents Market was valued at USD 220.0 million in 2025 and is projected to reach USD 340.0 million by 2032, expanding at a CAGR of 6.4% during 2026–2032, according to Strategic Market Research.

 

An esophageal stent is a tubular device placed across a narrowed or obstructed segment of the esophagus to maintain luminal patency and restore the ability to swallow. Companies such as Boston Scientific and Cook Medical compete through stent design, coverage options, deployment systems, and physician adoption.. [1]

 

The esophageal stents market is dominated by covered self-expanding metal stents, with recent FDA clearances from Merit Medical, Taewoong Medical, and Boston Scientific highlighting ongoing refinement in delivery, fixation, covering, and removability rather than a drug-style clinical pipeline. Demand is supported by both malignant and benign disease: SEER projects 22,530 U.S. esophageal cancer cases in 2026, while inpatient data show rising stent use for perforation, bleeding, and other non-cancer indications, broadening the addressable patient base.

 

Key Esophageal Stents Market Takeaways Across Products, Applications and Regions

Product Type

• Fully Covered Stents — 55.0% share, USD 121.0 million in 2025 and 7.1% CAGR; lead because removability and reduced tissue ingrowth support malignant obstruction, fistulas and selected refractory benign strictures.

• Partially Covered Stents — 32.0% share, USD 70.4 million in 2025 and 5.8% CAGR; remain important where stronger tissue anchoring is preferred, although embedment can complicate removal.

• Uncovered Stents — 13.0% share, USD 28.6 million in 2025 and 4.7% CAGR; retain a narrower role where fixation is prioritized and later retrieval is not expected.

 

Material

• Metal — 84.0% share, USD 184.8 million in 2025 and 6.6% CAGR; dominates through self-expanding nitinol platforms that combine radial support, flexibility and established malignant-stricture use.

• Plastic — 16.0% share, USD 35.2 million in 2025 and 5.3% CAGR; represents non-metal/polymer-based systems in the SMR taxonomy, including specialized biodegradable platforms where applicable.

 

Application

• Malignant Esophageal Strictures — 58.0% share, USD 127.6 million in 2025 and 5.8% CAGR; remains the core commercial indication because SEMS can provide rapid palliation of obstructive dysphagia.

• Benign Esophageal Strictures — 20.0% share, USD 44.0 million in 2025 and 7.8% CAGR; the fastest application segment, but commercial opportunity is concentrated in refractory disease rather than routine first-line use.

• Esophageal Fistulas & Leaks — 15.0% share, USD 33.0 million in 2025 and 7.2% CAGR; covered stents provide temporary sealing while maintaining lumen patency in selected malignant and postsurgical cases.

• Others — 7.0% share, USD 15.4 million in 2025 and 6.0% CAGR; includes selected perforations, bleeding-related use and other complex therapeutic-endoscopy indications.

 

End User

• Hospitals — 72.0% share, USD 158.4 million in 2025 and 6.1% CAGR; lead because advanced cancer obstruction, fistulas and perforations often require multidisciplinary and high-acuity support.

• Ambulatory Surgical Centers — 18.0% share, USD 39.6 million in 2025 and 7.5% CAGR; gain from selected scheduled therapeutic-endoscopy cases that can be managed without inpatient admission.

• Specialty Clinics — 10.0% share, USD 22.0 million in 2025 and 6.8% CAGR; participate in selected endoscopy procedures and follow-up where hospital-level backup is not required.

 

Region

• North America — 38.0% share, USD 83.6 million in 2025 and 5.8% CAGR; leads through advanced therapeutic-endoscopy infrastructure, oncology care and a broad FDA-cleared device base.

• Europe — 29.0% share, USD 63.8 million in 2025 and 5.9% CAGR; combines guideline-defined stent use, mature public procurement and access to conventional and biodegradable products.

• Asia-Pacific — 25.0% share, USD 55.0 million in 2025 and 8.1% CAGR; records the fastest regional growth profile, supported by cancer burden, endoscopy capacity and a strong Asian manufacturing ecosystem.

• LAMEA — 8.0% share, USD 17.6 million in 2025 and 6.7% CAGR; remains concentrated in tertiary centers where advanced endoscopy, oncology support and distributor coverage are available.

 

Malignant, Benign and Complex Esophageal Indications Shaping Market Opportunity

Malignant esophageal strictures accounted for 58.0% of the market, representing USD 127.6 million in 2025, and are projected to expand at a CAGR of 5.8% during 2026–2032. The segment remains the principal revenue pool because advanced esophageal and gastro-esophageal junction tumors can produce dysphagia that requires rapid restoration of swallowing. ESGE recommends partially or fully covered SEMS for palliation of malignant dysphagia, while NICE recommends self-expanding stents when immediate dysphagia relief is required. Portfolios from Boston Scientific and Cook Medical therefore remain anchored in malignant-stricture and fistula indications rather than broad use across all stages of esophageal cancer. [3,4,20,22]

Benign esophageal strictures accounted for 20.0% of the market, equivalent to USD 44.0 million in 2025, and are projected to expand at a CAGR of 7.8%. This is the fastest-growing application in the SMR model, but its addressable population is deliberately narrower than the total benign-stricture population. ESGE recommends against SEMS as first-line therapy and supports temporary stenting in refractory strictures, with fully covered SEMS preferred over partially covered designs because of lower embedment and easier removal. ELLA-CS adds a differentiated option through a polydioxanone biodegradable stent that typically degrades within three to four months and is intended for benign strictures resistant to standard therapy. [3,24]

Esophageal fistulas & leaks held 15.0% of the market, representing USD 33.0 million in 2025, and are projected to grow at a CAGR of 7.2%. Covered stents can isolate a defect while preserving luminal continuity, supporting use in malignant tracheoesophageal or bronchoesophageal fistulas and selected postoperative or iatrogenic leaks. ESGE recommends SEMS for malignant fistula sealing and allows temporary stenting for leaks, fistulas and perforations. Merit Medical's Resilience clearance includes occlusion of esophageal fistulae, while Cook Medical's fully covered Evolution is indicated for malignant strictures and tracheoesophageal fistulas. [3,8,22]

Other applications represented 7.0% of the market, equivalent to USD 15.4 million in 2025, with a CAGR of 6.0%. Perforation is the most commercially relevant indication within this residual group because stenting can provide a minimally invasive alternative to surgical repair in selected cases. A Premier Healthcare Database analysis of 2,543 patients treated during 2009–2019 found that stenting rose from 7.0% to 78.1% of studied interventions. After adjustment, death or hospice discharge was similar between stenting and surgical repair, while hospital length of stay was shorter with stenting. The finding supports a role for removable covered systems in acute-care endoscopy without implying that stents replace surgery across all perforations. [6]

 

Fully Covered SEMS and Nitinol Platforms Strengthening Market Leadership

Fully covered stents accounted for 55.0% of the Esophageal Stents Market, representing USD 121.0 million in 2025, and are projected to expand at a CAGR of 7.1%. Covering limits tissue and tumor ingrowth and can make retrieval more feasible when temporary therapy is required, although migration remains a design trade-off. Merit's Resilience uses a fully covered nitinol architecture with a double-flange design and a through-the-scope delivery system, while Cook Medical's Evolution fully covered platform is positioned for malignant strictures and tracheoesophageal fistulas. The commercial importance of this segment is therefore tied to removability and broader applicability across malignant and selected benign complications rather than covering alone. [3,9,22]

Partially covered stents held 32.0% of the market, representing USD 70.4 million in 2025, and are projected to grow at a CAGR of 5.8%. Exposed stent ends permit tissue integration that can improve fixation, but embedded metal may make later removal more difficult. Boston Scientific's WallFlex and M.I.Tech's HANAROSTENT portfolios provide covered and partially covered options, allowing physicians to balance migration resistance against removability according to the lesion and expected duration of stenting. [20,19]

Uncovered stents represented 13.0% of the market, equivalent to USD 28.6 million in 2025, and are projected to expand at a CAGR of 4.7%. Their commercial role is more selective because exposed mesh can permit tumor or tissue ingrowth and limits retrieval. Boston Scientific continues to market covered and uncovered Ultraflex configurations for malignant esophageal strictures, illustrating that uncovered products remain clinically relevant where fixation and permanent palliation are prioritized. [21]

Metal stents dominated the material category with an 84.0% share, representing USD 184.8 million in 2025, and are projected to grow at a CAGR of 6.6%. Self-expanding nitinol frames can be compressed into delivery systems and then apply outward radial force after deployment; current platforms add silicone coverings, radiopaque markers, retrieval sutures and anti-migration geometry. Taewoong, M.I.Tech/Olympus, Boston Scientific and Merit Medical all compete within this metal-based architecture, making design execution and delivery profile more important than the basic material itself. [10,19,20,23]

Plastic accounted for 16.0% of the market, representing USD 35.2 million in 2025, and is projected to grow at a CAGR of 5.3%. Within this report's material taxonomy, the category includes non-metal and polymer-based esophageal stent technologies, including biodegradable polymers where applicable. Its smaller position reflects the dominance of nitinol SEMS in current malignant-obstruction portfolios, while biodegradable polydioxanone provides a distinct niche in refractory benign strictures because the device does not require planned removal after degradation. [24]

 

TTS Delivery, Anti-Migration Designs and Biodegradable Stents Transforming Product Competition

Through-the-scope delivery is becoming a visible competitive feature. Olympus's HANAROSTENT Esophagus TTS uses a 10.5F delivery catheter and is offered in fully and partially covered configurations, allowing deployment under direct endoscopic visualization. Merit Medical launched its Resilience TTS system in April 2026 after receiving FDA clearance in July 2025. Taewoong's TTS platform likewise uses a 10.5F introducer, although its October 2025 K243619 filing largely represented a change in suture material and indication alignment rather than a first entry into TTS esophageal stenting. For buyers, the shift makes catheter profile, deployment control and visualization more relevant alongside stent diameter and covering. [19,8,9,10]

Migration management remains a central design problem because the features that improve removability can reduce fixation. Boston Scientific uses progressive flared ends in WallFlex, while Merit Medical describes Resilience's double-flange configuration as an anti-migration feature. M.I.Tech/Olympus uses dumbbell-shaped ends in its TTS portfolio. These approaches compete on the balance among radial force, axial force, conformability and retrievability rather than on a single performance attribute. [20,9,19]

Biodegradable stents remain a small but strategically differentiated technology. ELLA-CS's BD Stent is made from polydioxanone, maintains integrity and radial force for approximately six to eight weeks, and typically degrades within three to four months. Because the product is intended for benign strictures resistant to standard therapy, its commercial value lies in temporary support without a planned removal procedure rather than direct substitution for every conventional SEMS placement. [24]

Recent FDA activity also needs to be interpreted by the type of submission. M.I.Tech received a Special 510(k) decision for HANAROSTENT Esophagus Upper in October 2025, and Boston Scientific's July 2026 Special 510(k) for WallFlex/Agile addressed an overmolded delivery-catheter tip process after earlier commercial configurations. This distinction matters commercially: a new clearance can represent a new platform, a line extension or a manufacturing/product modification, and those events should not be treated as equivalent competitive launches. [27,11]

Post-market performance can influence hospital purchasing as directly as new product features. FDA classified a 2024 recall involving specified WallFlex and Agile esophageal stent lots because of potential delivery-catheter tip detachment. The action was limited to identified products and lots, but it reinforces the importance of deployment-system reliability, supplier quality controls and corrective action in a market where hospitals depend on predictable device release in high-risk procedures. [12]

 

Hospital Adoption, Reimbursement Pathways and Procurement Trends in Esophageal Stenting

Hospitals accounted for 72.0% of the Esophageal Stents Market, representing USD 158.4 million in 2025, and are projected to expand at a CAGR of 6.1%. The setting dominates because malignant obstruction, perforation and fistula cases often require advanced endoscopy, anesthesia, imaging, surgical backup, oncology input and post-procedure monitoring. The National Inpatient Sample evidence showing a broader benign-indication mix further supports the continued importance of urban teaching and tertiary hospitals in the procedure base. [5,7]

Ambulatory Surgical Centers accounted for 18.0% of the market, representing USD 39.6 million in 2025, and are projected to grow at a CAGR of 7.5%. The forecast reflects the suitability of selected planned esophageal-stent procedures for outpatient management when the indication, patient condition and facility capabilities permit it. This should not be interpreted as evidence that high-acuity cancer, fistula or perforation cases are broadly shifting away from hospitals; the commercial opportunity is concentrated in carefully selected lower-complexity procedures and efficient endoscopy workflows.

Specialty clinics held 10.0% of the market, representing USD 22.0 million in 2025, and are projected to expand at a CAGR of 6.8%. Their role is concentrated in specialist gastroenterology and therapeutic-endoscopy settings that can provide planned procedures, reassessment and follow-up. The segment remains smaller than hospitals because migration, recurrent obstruction, fistula management and possible stent removal can require escalation to broader multidisciplinary support.

Payment pathways are visible but should be interpreted carefully. In the United States, CMS's Medicare Coverage Database includes billing and coding guidance for diagnostic and therapeutic EGD through Article A57063 linked to Local Coverage Determination L33583; it is a Medicare Administrative Contractor coverage framework rather than a national esophageal-stent coverage determination. Australia provides a dedicated procedure code: MBS Item 30490 covers insertion of an oesophageal prosthesis, including endoscopy and dilatation, with a schedule fee of AUD 630.05 from July 1, 2026. Neither figure represents a device selling price. [13,14]

Public procurement shows that suppliers compete on more than unit price. NHS Scotland's current Flexible Video Endoscopy framework includes oesophageal stents within the stents lot and weights award criteria across quality, support and service, sustainability and cost. The framework value spans multiple endoscopy stent categories and must not be read as esophageal-stent revenue, but the award structure illustrates why product reliability, clinical support and supply continuity influence commercial access alongside price. [15]

 

Regional Esophageal Stents Market Opportunities Across North America, Europe, Asia-Pacific and LAMEA

North America accounted for 38.0% of the Esophageal Stents Market, representing USD 83.6 million in 2025, and is projected to expand at a CAGR of 5.8%. The region combines mature therapeutic-endoscopy infrastructure with a substantial malignant-disease pool: SEER estimates 22,530 U.S. esophageal cancer cases in 2026, while the Canadian Cancer Society projects approximately 2,800 diagnoses and 2,500 deaths in Canada in 2026. Recent product activity from Merit Medical and continuing portfolios from Boston Scientific, M.I.Tech/Olympus, Taewoong and other cleared suppliers keep competition focused on delivery workflow, migration control and product breadth rather than basic availability. [2,17,8,19,20]

Europe held 29.0% of the market, equivalent to USD 63.8 million in 2025, and is forecast to grow at a CAGR of 5.9%. Cancer Research UK reports 9,525 new oesophageal cancer cases per year using 2019 and 2021–2022 data, while NICE and ESGE provide explicit guidance for malignant dysphagia, refractory benign strictures, fistulas, leaks and perforations. The region also supports a broader technology mix, including ELLA-CS biodegradable products and specialist stent suppliers such as Leufen, while public purchasing frameworks place visible weight on clinical quality and service capability. [16,3,4,24,29]

Asia-Pacific represented 25.0% of the market, or USD 55.0 million in 2025, and is projected to expand at the fastest regional CAGR of 8.1%. The opportunity combines esophageal-cancer burden, expanding therapeutic-endoscopy capacity and a strong regional manufacturing base. Japan's National Cancer Center East reports more than 16,000 endoscopic procedures and about 2,500 endoscopic resections annually and specifically lists stent placement among palliative treatments for symptomatic advanced cancer. South Korea is home to M.I.Tech and Taewoong, while China-based Micro-Tech maintains a broad esophageal-stent portfolio, giving the region both a patient-access and supplier-side growth mechanism. [18,25,27]

Latin America is estimated by Strategic Market Research to account for 5.0% of the global market, or USD 11.0 million in 2025, and to expand at approximately 6.5% CAGR. The opportunity is concentrated in larger tertiary gastroenterology and oncology centers where advanced endoscopy, fluoroscopy, anesthesia and complication management are available. Distributor reach, inventory reliability and price sensitivity are more influential than extensive portfolio breadth in many public and private hospital accounts.

The Middle East & Africa is estimated by Strategic Market Research to represent 3.0% of the global market, or USD 6.6 million in 2025, and to expand at approximately 7.0% CAGR. Commercial activity remains concentrated in major referral hospitals and oncology centers, with wider access constrained by the uneven distribution of therapeutic-endoscopy expertise and supporting infrastructure. These Latin America and Middle East & Africa estimates are an SMR analyst allocation of the supplied 8.0% LAMEA share and preserve an approximately 6.7% weighted LAMEA growth profile.

 

Competitive Landscape of Leading Esophageal Stent Manufacturers and Product Portfolios

Competition in the Esophageal Stents Market is concentrated around self-expanding metal platforms, covering architecture, migration resistance, removability, catheter profile, deployment control, lesion-specific sizing and geographic commercialization. Large gastrointestinal-device companies compete alongside specialist Asian and European manufacturers, while recent TTS products are shifting part of the competitive conversation from stent patency alone toward procedure workflow and positioning control.

Boston Scientific Corporation
Boston Scientific competes with WallFlex and Ultraflex esophageal stent systems. WallFlex is available in fully and partially covered configurations and combines silicone covering, flared ends and a braided nitinol structure; Ultraflex remains available in covered and uncovered configurations for malignant esophageal strictures. The July 2026 K261978 Special 510(k) addressed an overmolded delivery-catheter tip process rather than a new indication or a first launch, an important distinction when assessing competitive momentum. [20,21,11]

Merit Medical Systems
Merit Medical's Endotek portfolio includes Alimaxx-ES and EndoMAXX fully covered esophageal stents and the newer Resilience TTS system. FDA cleared Resilience under K251265 in July 2025, and Merit lists the product as launched in April 2026. The 2025 Form 10-K also identifies Resilience, Alimaxx-ES and EndoMAXX as part of Merit's current gastroenterology offering, giving the company both established OTW-style covered platforms and a newer TTS option. [8,9,23]

Cook Medical
Cook Medical competes through the Evolution Esophageal Controlled-Release family. Its U.S. fully covered and partially covered products are intended to maintain patency in malignant esophageal strictures and seal tracheoesophageal fistulas. Controlled deployment and a focused esophageal portfolio position Cook as a specialist alternative within hospital endoscopy accounts rather than a vendor competing through the widest number of near-identical configurations. [22]

M.I.Tech Co., Ltd. / Olympus
M.I.Tech manufactures the HANAROSTENT esophageal family, while Olympus commercializes TTS esophageal products in the United States. HANAROSTENT TTS uses a 10.5F catheter and is offered in fully and partially covered versions. M.I.Tech also received an October 2025 Special 510(k) decision for HANAROSTENT Esophagus Upper, extending the company's lesion-specific portfolio. The relationship gives M.I.Tech access to Olympus's endoscopy customer base while preserving M.I.Tech as the device manufacturer. [19,27]

Taewoong Medical
Taewoong competes through its Niti-S esophageal platform and TTS delivery system. FDA's October 2025 K243619 submission states that the subject devices were identical to previously cleared systems except for a suture-material change, with the Niti-S indication also aligned to include occlusion of concurrent esophageal fistulas. This makes the clearance a product-maintenance and indication-alignment event rather than a wholly new U.S. platform launch. Taewoong remains independent; Olympus rescinded its acquisition agreement in March 2024. [10,28]

Micro-Tech Endoscopy
Micro-Tech participates with covered, segmented and anti-reflux esophageal stent designs. Its anti-reflux system uses a self-expanding nitinol mesh and valve concept intended to limit reflux when the cardia is bridged, while FDA clearance of its Segmented Esophageal Stent System provides a U.S. regulatory base for the broader franchise. The company adds meaningful price and design competition from the Chinese manufacturing ecosystem. [25,30]

ELLA-CS
ELLA-CS differentiates through biodegradable and specialist esophageal systems rather than competing only on conventional covered SEMS. Its polydioxanone BD Stent is intended for benign strictures resistant to standard therapy and typically degrades within three to four months. The absence of a planned removal procedure gives the product a distinct position in the refractory-benign niche, where guideline-constrained use still leaves room for temporary-support technologies. [24]

Thoracent
Thoracent is a smaller U.S. participant with FDA-cleared HILZO Esophageal Stents. FDA granted a substantially equivalent decision under K223266 in January 2024. Its presence is relevant because it shows that competition is not limited to the largest multinational GI suppliers and that smaller manufacturers can enter the Class II esophageal-prosthesis market through the 510(k) pathway. [26]

Leufen Medical
Leufen Medical's aixstent portfolio includes the OES esophageal stent, OEL leakage stent and OEC cardia umbrella configuration. The OES line includes partial and full silicone coverings and a 24F OTW delivery system, while the fully covered version is also registered for benign indications in applicable markets. This specialized portfolio supports competition in European and distributor-led accounts where manufacturers can differentiate through indication-specific geometries rather than scale alone. [29]

 

Esophageal Stents Market Strategic Outlook and Commercial Opportunities Through 2032

Strategic Market Research expects the market's 6.4% CAGR to be shaped less by broad esophageal-cancer incidence alone and more by the mix of procedures that actually convert into stent use. Malignant dysphagia remains the largest revenue base, while refractory benign strictures, fistulas, leaks and selected perforations provide the higher-growth pockets. The benign opportunity is commercially attractive but clinically capped because guidelines reserve SEMS for refractory disease rather than uncomplicated first-line strictures. [3,4]

Fully covered systems are positioned to remain strategically important because the faster-growing applications place greater value on removability and temporary treatment. That advantage is counterbalanced by migration risk, which keeps fixation geometry, radial and axial force, and retrieval features central to physician selection. Manufacturers that can offer several lengths, diameters and covering configurations without adding unnecessary deployment complexity should be better positioned in hospital formularies.

TTS delivery is likely to become a more visible competitive battleground rather than a separate clinical category. Merit, M.I.Tech/Olympus and Taewoong now give buyers multiple TTS options, and Boston Scientific's Agile portfolio also includes smaller-diameter TTS configurations outside the specific 23 mm OTW change addressed by K261978. The strategic question is therefore whether easier visualization and catheter handling translate into repeatable physician preference and account-level switching, not whether TTS changes the underlying disease indication. [19,10,11]

Hospitals should remain the dominant purchasing setting through 2032 because complex cancer obstruction, fistulas and perforations require infrastructure that is difficult to replicate across all outpatient sites. At the same time, selected planned cases can support faster growth in ambulatory settings. Procurement evidence from NHS Scotland also indicates that vendor evaluation extends beyond acquisition cost to quality, support, service and supply performance, which favors manufacturers able to support clinical teams consistently. [15]

Asia-Pacific offers the strongest regional growth profile in the SMR model at 8.1%, combining procedure-capacity expansion with manufacturing strength in South Korea and China. North America and Europe remain the largest mature revenue pools, but competitive gains there are more likely to come from product replacement, workflow improvements, new sizes and selective indication expansion than from simple first-time access. For CEOs and commercial teams, the highest-value opportunities are therefore the intersections of indication expansion, removable covered designs, TTS workflow, migration control and reliable hospital commercialization.

 

Market Scope, Research Methodology and Evidence Base

Strategic Market Research's supplied 2025 market size, 2032 forecast, CAGR and segment shares were retained as the authoritative quantitative baseline. Segment market values were calculated directly from the USD 220.0 million 2025 total; each supplied segmentation category sums to 100%. The implied CAGR from USD 220.0 million in 2025 to USD 340.0 million in 2032 is approximately 6.4%, confirming mathematical consistency with the supplied forecast.

Clinical and commercial interpretation was grounded in primary or authoritative sources, including FDA 510(k) and recall records, NCI/SEER, NICE, ESGE, CMS Medicare Coverage Database materials, the Australian Medicare Benefits Schedule, NHS Scotland procurement records, peer-reviewed utilization studies, recognized cancer organizations, company SEC filings and official product pages. No competing market-research company's market size, share or CAGR was used. Latin America and Middle East & Africa were estimated only to disaggregate the supplied 8.0% LAMEA total; the 5.0%/3.0% allocation preserves the supplied combined share and an approximately 6.7% weighted growth profile.

SMR Market Scope

This RD covers dedicated esophageal stent/prosthesis systems used for malignant esophageal obstruction, refractory benign strictures, fistulas, leaks, perforations and other included esophageal indications. It excludes biliary, duodenal, colonic, airway and vascular stents. Market values refer to the esophageal stent device market and should not be interpreted as procedure reimbursement or total treatment cost.

 

Esophageal Stents Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 220.0 Million
Revenue Forecast in 2032	USD 340.0 Million
Overall Growth Rate	CAGR of 6.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Material, By Application, By End User, By Geography
By Product Type	Fully Covered Stents, Partially Covered Stents, Uncovered Stents
By Material	Metal, Plastic
By Application	Malignant Esophageal Strictures, Benign Esophageal Strictures, Esophageal Fistulas & Leaks, Others
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Japan, South Korea, China, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Malignant dysphagia palliation, growing use in refractory benign strictures, fistulas, leaks and selected perforations, adoption of removable fully covered stents, development of through-the-scope delivery systems, anti-migration designs, expanding therapeutic-endoscopy capacity, and a strong Asia-Pacific manufacturing ecosystem
Customization Option	Available upon request